Global Neutropenia Market, By Type (Congenital Neutropenia, Idiopathic Neutropenia, Cyclic Neutropenia, Autoimmune Neutropenia, Others), Treatment (Antibiotic Therapy, Colony-Stimulating Factor Therapy, Granulocyte Transfusion, Splenectomy Procedure, Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Neutropenia Market Analysis and Size
The neutropenia market is expected to witness significant growth during the forecast period. The neutropenia market is mainly boosted by high prevalence of cancer where chemotherapy is the primary treatment which causes chemotherapy, induced neutropenia and promising pipeline drugs. Multiple treatment landscape and effective diagnosis are considered positive indicators for the demand for the growth of neutropenia market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global neutropenia market in the forecast period 2022-2029. The expected CAGR of global neutropenia market is tend to be around 5.50% in the mentioned forecast period. The market was valued at USD 13.2 billion in 2021, and it would grow upto USD 20.26 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Neutropenia is haematological disorder which are characterized by abnormally low concentration of neutrophils that leads to a compromised immune system. These are a type of white blood cells which is an essential component of blood that helps in the fighting against infections. Low count of neutrophils can lead to spectrum of distressing infectious diseases. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Neutropenia Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Congenital Neutropenia, Idiopathic Neutropenia, Cyclic Neutropenia, Autoimmune Neutropenia, Others), Treatment (Antibiotic Therapy, Colony-Stimulating Factor Therapy, Granulocyte Transfusion, Splenectomy Procedure, Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Merck & Co., Inc. (U.S.), AstraZeneca (U.K.), Cipla Inc. (U.S.), Abbott (U.S.), Bausch Health Companies Inc. (Canada), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Seagen, Inc (U.S.), ONO Pharmaceutical Co., Ltd. (Japan), Coherus BioSciences (U.S.)
|
|
Market Opportunities
|
|
Global Neutropenia Market Dynamics
Drivers
- Increasing Investments by Market Players
Several growth strategies such as novel product launches aid in leading market players gain a competitive edge over the other players, in the upcoming years. Collaboration between major market players and smaller players can help increase their revenue shares. The smaller market leaders will acquire investments from private investors, which in turn could help them in their long-term growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increase in Cancer Cases
The rising prevalence of cancer is boosting the growth of the market. The incidence of patients with cancer in India among males was 679,421 and that for females was 712,758 for the year 2020. Thus, it boosts the market growth.
- Rising Healthcare Awareness
Health awareness amongst the population are rising which results in the prediction of drugs to boost the market growth. The innovative launches in medications for the treatment of ovarian cancer are expected to prompt the market simultaneously. Different researchers are investing in launching drugs that benefit the market. For instance, several novel products such as Taiho Pharmaceutical’s drugs, ZOSYN 2.5, ZOSYN 4.5 for I.V. infusion bag, and ZOSYN 4.5 are in the pipeline and these products are expected to change the treatment growth. This creates more opportunity in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global neutropenia market over a forecast period.
- High Cost
The huge expenditure of the treatment methods surely hamper the market growth. Many times, due to lack of appropriate payment plans and special considerations by the organizations, the patients fail to adapt these high-end treatment options which in return hampers their health. Thus, this is an important restrain that needs to be taken care of.
This global neutropenia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global neutropenia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Neutropenia Market Scope
The global neutropenia market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Congenital Neutropenia
- Idiopathic Neutropenia
- Cyclic Neutropenia
- Autoimmune Neutropenia
- Others
Treatment
- Antibiotic Therapy
- Colony-Stimulating Factor Therapy
- Granulocyte Transfusion
- Splenectomy Procedure
- Others
Route of Administration
- Oral
- Injectable
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Neutropenia Market Regional Analysis/Insights
The global neutropenia market is analysed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global neutropenia market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the high demand for disease-specific treatment, rise in adoption of newer technologies, presence of refined healthcare expenditure, increased patient awareness level, and high prevalence of bleeding disorders.
Asia-Pacific dominates the market due to the number of generic manufacturers in this region and increasing disposable income.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Neutropenia Market Share Analysis
The global neutropenia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global neutropenia market.
Key players operating in the global neutropenia market include:
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Merck & Co., Inc. (U.S.)
- AstraZeneca (U.K.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- Bausch Health Companies Inc. (Canada)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Amneal Pharmaceuticals LLC. (U.S.)
- Seagen, Inc (U.S.)
- ONO Pharmaceutical Co., Ltd. (Japan)
- Coherus BioSciences (U.S.)
SKU-